These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 32455818)

  • 1. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer.
    D'Aguanno S; Del Bufalo D
    Cells; 2020 May; 9(5):. PubMed ID: 32455818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?
    Brinkmann K; Ng AP; de Graaf CA; Strasser A
    Cell Death Differ; 2022 Jun; 29(6):1079-1093. PubMed ID: 35388168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
    Scarfò L; Ghia P
    Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
    Modi V; Sankararamakrishnan R
    J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dynamic simulations on an inhibitor of anti-apoptotic Bcl-2 proteins for insights into its interaction mechanism for anti-cancer activity.
    Anantram A; Kundaikar H; Degani M; Prabhu A
    J Biomol Struct Dyn; 2019 Aug; 37(12):3109-3121. PubMed ID: 30526410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL-2 protein family: attractive targets for cancer therapy.
    Kaloni D; Diepstraten ST; Strasser A; Kelly GL
    Apoptosis; 2023 Feb; 28(1-2):20-38. PubMed ID: 36342579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.
    Mukherjee N; Strosnider A; Vagher B; Lambert KA; Slaven S; Robinson WA; Amato CM; Couts KL; Bemis JGT; Turner JA; Norris DA; Shellman YG
    Cell Death Dis; 2018 Sep; 9(9):907. PubMed ID: 30185782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins.
    Pal P; Zhang P; Poddar SK; Zheng G
    Expert Opin Ther Pat; 2022 Sep; 32(9):1003-1026. PubMed ID: 35993382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.
    Pécot J; Maillet L; Le Pen J; Vuillier C; Trécesson SC; Fétiveau A; Sarosiek KA; Bock FJ; Braun F; Letai A; Tait SWG; Gautier F; Juin PP
    Cell Rep; 2016 Dec; 17(12):3347-3358. PubMed ID: 28009301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
    Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
    Sarosiek KA; Letai A
    FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
    Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
    Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
    Suvarna V; Singh V; Murahari M
    Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.